VIVEbiotech at Advanced Therapies Congress 2026 in London: Key Insights and Industry Connections
Lentiviral vector innovation, collaboration, and new opportunities in cell and gene therapy at ExCeL London.
VIVEbiotech has successfully concluded its participation at the Advanced Therapies Congress 2026, held at ExCeL London, one of the leading events in the field of cell and gene therapy.
Organized by Terrapinn, the Advanced Therapies Congress in London brought together a global community of experts, biotech companies, and industry leaders focused on advancing cell and gene therapies. The event provided a valuable platform to exchange knowledge, explore innovation, and discuss the future of advanced therapies.
During the two-day congress, the VIVEbiotech team actively engaged with partners and stakeholders across the advanced therapies ecosystem. Key discussions focused on current industry challenges, future development needs, and the critical role of lentiviral vectors in next-generation treatments, including both ex vivo and in vivo applications.
VIVEbiotech thanks all professionals who connected with the team during the Advanced Therapies Congress 2026. These interactions continue to reinforce the importance of collaboration in driving innovation in cell and gene therapy.
From early-stage development to commercial manufacturing, VIVEbiotech remains committed to supporting lentiviral vector development and manufacturing, contributing to the advancement of next-generation gene therapies worldwide.